Key facts
- HaystackAnalytics’s last known valuation is $70.0M (Mar 2026).
- It has raised $15.0M.
- Notable investors include Society for Innovation and Entrepreneurship, BIRAC, 1Crowd, Aeroflex Enterprises, Alkem Laboratories — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for HaystackAnalytics
- ·The full record, as it builds
Funding rounds
No funding rounds for HaystackAnalytics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HaystackAnalytics
Developer of genomic diagnostic tools designed for the rapid identification of infectious diseases. The company's platform utilizes next-generation sequencing and bioinformatics to detect a wide range of pathogens and identify antimicrobial resistance genes, rapidly delivering results, enabling healthcare providers in clinical settings to make faster, evidence-based treatment decisions and improve patient outcomes.
- Sector
- Healthcare
- HQ
- Mumbai, India
- Founded
- 2018
- Employees
- 177
- Website
- haystackanalytics.in/
- Ownership
- Privately Held (backing)
HaystackAnalytics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HaystackAnalytics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HaystackAnalytics in its N-PORT filings yet. We sweep new filings monthly.